MediPharm Labs Corp (MLZ.SG)
| Previous close | 0.0444 |
| Open | 0.0494 |
| Bid | 0.0442 x 0 |
| Ask | 0.0680 x 0 |
| Day's range | 0.0442 - 0.0494 |
| 52-week range | 0.0269 - 0.0716 |
| Volume | |
| Avg. volume | 944 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
MediPharm Labs Provides Conference Call Recording Details
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023.
- PR Newswire
MediPharm Labs Reports Fourth Quarter and Full Year Results
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.
- PR Newswire
MediPharm Labs Provides Update on German Cannabis Legalization
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on German cannabis legalization.
